Quick Answer
CNBX Pharmaceuticals Inc. reported R&D Expense of $0.00 for fiscal year 2025.
CNBX Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $194.8K | -54.9% |
| 2023 | $431.6K | -63.5% |
| 2022 | $1.18M | -33.2% |
| 2021 | $1.77M | +5.3% |
| 2020 | $1.68M | +9.0% |
| 2019 | $1.54M | +53.8% |
| 2018 | $1.00M | +306.5% |
| 2017 | $246.9K | +39.0% |
| 2016 | $177.6K | +27.4% |
| 2015 | $139.4K | — |
| 2014 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| May 31, 2025 | $0.00 | -100.0% | — |
| February 28, 2025 | $0.00 | -100.0% | — |
| November 30, 2024 | $0.00 | -100.0% | -100.0% |
| May 31, 2024 | $42.9K | -83.7% | -60.0% |
| February 29, 2024 | $107.2K | +769.6% | -4.6% |
| November 30, 2023 | $112.4K | +78.8% | -57.3% |
| May 31, 2023 | $263.1K | +5.6% | +2034.3% |
| February 28, 2023 | $12.3K | -96.3% | -80.4% |
- CNBX Pharmaceuticals Inc. showed a decrease of -100.0% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: